Review Article
Combined Therapy of Diabetic Peripheral Neuropathy with Breviscapine and Mecobalamin: A Systematic Review and a Meta-Analysis of Chinese Studies
Table 1
Characteristics of included studies.
| Trial | Number | Age (Y) | Duration of diabetes (Y) | Duration of DPN (Y) | Treatment drugs/day | Main outcome measures | Course of treatment |
Adverse events | B + M | M | (B + M/M) | (B + M/M) | (B + M/M) | (B + M/M) | B + M | M |
| Shi et al. (2013) [25] | 90 (45/45) | 58.4 ± 11.2/57.9 ± 10.8 | 11.2 ± 2.3/10.7 ± 2.6 | 3.01 ± 0.93/3.15 ± 0.87 | 50 mg iv. | 1.5 mg n.r. | 1.5 mg n.r. | TER, SNCV, MNCV | 6 w | 0 | Lan and Wu (2010) [26] | 82 (43/39) | 53.2 ± 3.7/53.6 ± 3.6 | 9.3 ± 8.3/9.54 ± 3.1 | 4.3 ± 1.3/4.2 ± 1.2 | 150 mg ivgtt. | 0.5 mg im. | 0.5 mg im. | TER, SNCV | 4 w |
n.r. | Chang (2007) [29] | 86 (43/43) | 69.4/63.7 | 12.0/11.0 | 4/3.5 | 40 mL ivgtt. | 0.5 mg po. | 0.5 mg po. | TER, SNCV, MNCV | 30 d | 5/0 | Chen and Shao (2008) [30] | 132 (68/64) | 72 ± 12.3/69 ± 11.9 | n.r. | n.r. | 30 mL ivgtt. | 1.5 mg po. | 1.5 mg po. | TER | 2 w | 2/0 | Duan and Yan (2004) [31] | 64 (36/28) | 55.5 ± 5.2 | 5.5 ± 4.2/n.r. | 3.6 ± 2.5/n.r. | 30 mL ivgtt. | 0.5 mg im. | 0.5 mg im. | TER, SNCV, MNCV | 6 w | n.r. | Feng et al. (2009) [32] | 91 (46/45) | n.r. | n.r. | n.r. | 20 mL ivgtt. | 1.0 mg ivgtt. | 1.0 mg ivgtt. | TER | 4 w | n.r. | Jin et al. (2010) [33] | 70 (35/35) | 57 ± 10/56 ± 10 | 8.5 ± 3.4/8.5 ± 3.2 | n.r. | 20 mL ivgtt. | 0.5 mg im. | 0.5 mg im. | TER, SNCV, MNCV | 4 w | n.r. |
Lan et al. (2007) [34] | 82 (43/39) | 53.2 ± 3.7/53.6 ± 3.6 | 9.3 ± 8.3/9.54 ± 8.1 | 4.3 ± 1.3/4.2 ± 1.2 | 150 mg ivgtt. | 0.5 mg im. | 0.5 mg im. | TER, SNCV | 4 w | n.r. | Li et al. (2009) [28] | 120 (64/56) | 60 ± 6.52/60.5 ± 8.33 | 5.5 ± 4.2 | 2.6 ± 0.4/2.8 ± 0.5 | 20 mL ivgtt. | 0.5 mg im. | 0.5 mg im. | TER, SNCV, MNCV | 4 w | 0 | Li et al. (2006) [35] | 56 (29/27) | 55 ± 3/56 ± 4 | 6.75 ± 1.2/6.8 ± 1.2 | 2.15 ± 0.21/1.98 ± 0.23 | 135 mg ivgtt. | 1.5 mg po. | 1.5 mg po. | TER | 4 w | 2/0 | Luo and Tang (2013) [36] | 80 (40/40) | 61.3 ± 12.08/62 ± 11.87 | 3.02 ± 1.75/3.04 ± 1.93 | 5.57 ± 2.03/5.42 ± 2.2 | 70 mg ivgtt. | 1.0 mg iv. | 1.0 mg iv. | TER, SNCV, MNCV | 2 w | n.r. | Peng et al. (2012) [37] | 88 (40/48) | 61.56 ± 12.18/62.36 ± 6.25 | 11.83 ± 2.3/12.04 ± 4.52 | 4.9/5.5 | 75 mg ivgtt. | 1.0 mg ivgtt. | 1.0 mg ivgtt. | TER, SNCV, MNCV | 2 w | n.r. | Sun (2014) [38] | 60 (30/30) | 53.2 ± 3.6/51.7 ± 2.8 | 10.6 ± 4.2/9.5 ± 3.4 | n.r. | 20 mL ivgtt. | 1.0 mg ivgtt. | 1.0 mg ivgtt. | TER, SNCV, MNCV | 2 w | n.r. | Wang (2013) [39] | 68 (34/34) | 62.4 ± 8.4 | n.r. | n.r. | 200 mg ivgtt. | 1.5 mg po. | 1.5 mg po. | TER | 4 w | 2.0/3.0 | Wu and Zhang (2007) [40] | 74 (38/36) | 48/47 | 7.34/7.28 | 2.32/2.24 | 40 mL ivgtt. | 500 mL im. | 500 mL im. | TER | 2–6 w | n.r. | Zhang (2012) [41] | 60 (30/30) | 59.06 ± 7.82 | 7.15 ± 1.32 | 2.06 ± 0.59 | 50 mg ivgtt. | 1.5 mg po. | 1.5 mg po. | TER | 4 w | 0 | Zhou (2009) [42] | 65 (33/32) | n.r. | n.r. | n.r. | 40 mL ivgtt. | 1.5 mg po. | 1.5 mg po. | TER | 4 w | 0 |
|
|